Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes

Drug Metabolism and Disposition

Volumn 27, Issue 10, 1999, Pages 1194-1199

  Ramachandran, Vinod ^c   Kostrubsky, Vsevolod E ^a   Komoroski, Bernard J ^c   Zhang, Shimin ^c   Dorko, Kenneth ^a   Esplen, James E ^a   Strom, Stephen C ^a   Venkataramanan, Raman ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; TROGLITAZONE;

ARTICLE; COATED PIT; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INSULIN SENSITIVITY; LIVER CELL CULTURE; LIVER PARENCHYMA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONTENT;

ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; CHROMANS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RIFAMPIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032852992     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Chang TK, Yu L, Maurel P and Waxman DJ (1997) Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocytes cultures: Response to cytochrome P450 induces and autoinduction by oxazaphosphorines. Cancer Res 57:1946-1954.
2. Crespi CL and Pennman BW (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Phamacol 43:171-188.
3. Gitlin N, Julie NL, Spun CL, Lim KN and Juarbe HM (1998) Two cases of severe clinical and histologic hepatoxicity associated with troglitazone. Ann Int Med 129:36-38.
4. Guillouzo A, Morel F, Langouet S, Maheo K and Rissel M (1997) Use of hepatocyte cultures for the study of hepatoxicity compounds. Toxicology 82 (Suppl 1-3):209-219.
5. Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T and Sugiyama Y (1996) Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 277:1630-1641.
6. Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, Defranco P, Bonomini L and Mulgaonkar SP (1998) Potential interaction of troglitazone and cyclosporine. Transplantation 65:1399-1400.
7. Kawai K, Kawasaki-Tokui Y, Odaka T, Tsuruta F, Kazui M, Iwabuchi H, Nakamura T, Kinoshita T, Ikeda T, Yoshioka T, Komai T and Nakamura K (1997) Disposition and metabolism of the new oral antidiabetic drag troglitazone in rats, mice and dogs. Arzneim-Forsch 47 (Suppl 4):356-368.
8. Kostrubsky VE, Lewis LD, Strom S, Wood SG, Schuetz EG, Schuetz JD, Sinclair PR, Wrighton SA and Sinclair JF (1998) Induction of cytochrome P4503A by Taxol in primary cultures of human hepatocytes. Arch Biochem Biophys 355:131-136.
9. Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA and Strom SC (1999) The use of human hepatocytes cultures to study induction of cytochrome P450. Drug Metab Dispos 27:887-894.
10. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR and Sinclair JF (1995) Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 322:516-520.
11. Koup JR, Anderson GD and Loi C (1998) Effect of troglitazone on urinary excretion of 6 ß-hydroxycortisol. J Clin Pharmacol 38:815-818.
12. Li AP (1997) Primary hepatocyte cultures as an in vitro experimental model for the evaluation of pharmacokinetic drug-drug interactions. Adv Pharmacol 43:103-130.
13. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL and Cheng LK (1997) Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin. Chem-Biol Interact 107:17-30.
14. Lowry O, Rosebrough N, Farr A and Randall R (1951) Protein measurement with the Polin phenol reagent. J Biol Chem 193:265-275.
15. Maurel P (1996) The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv Drug Deliv Rev 22:105-132.
16. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Qaiason SG, Phillips NJ and Brunt EM (1998) Troglitazone-induced hepatic failure leading to liver transplantation. Ann Int Med 129:38-41.
17. Pichard L, Fabre I, Fabre G, Domergue J, Aubert BS, Mourad G and Maurel P (1990) Cyclosporine A drug interactions. Drag Metab Dispos 18:595-606.
18. Rezulin Troglitazone tablets (package insert). Parke-Davis Pharmaceuticals Limited, July (1998).
19. Schuetz EG, Schuetz JD, Strom SC, Thompson MT, Fisher RA, Molowa DT, Li D and Guzelian PS (1993) Regulation of human liver cytochrome P450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology 18:1254-1262.
20. Strom SC, Dorko K, Thompson MT, Pisarov LA and Nussler AK (1998) Large scale isolation and culture of human hepatocytes. Ilots de Landerhans et hepatocytes: Vers une utilisation thérapeutique. (Franco D, Boudjema K and Varet B eds) pp 195-205, Institut National de la Santé et de la Recherche Medicale, Paris.
21. Strom SC, Pisarov LA, Dorko K, Thompson MT, Schuetz JD and Schuetz EG (1996) Use of human hepatocytes to study P450 gene induction. Methods Enzymol 72:388-401.
22. Venkatesan K (1992) Pharmacokinetic drug interactions with rifampicn. Clin Pharmacokinet 22:47-65.
23. Watkins PB and Whitcomb RW (1998) Hepatic dysfunction associated with troglitazone. New Engl J Med 338:916-917.
24. Waxman DJ, Ko A and Walsh C (1983) Regioselectivity and stereoselectivity of androgen hydroxylation catalyzed by cytochrome P450 isozymes purified from phenobarbital-induced rat liver. J Biol Chem 258:11937-11947.
25. Young MA, Lettis S and Eastmond R (1998) Co-administration of acetaminophen and troglitzone: Pharmacokinetics and safety. J Clin Pharmacol 38 (Suppl 9):819-825.